6533b7cffe1ef96bd1259a91
RESEARCH PRODUCT
Moving osimertinib to first-line: the right “strategy” in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?
Christian RolfoLuis E. RaezFrancesco Passigliasubject
Pulmonary and Respiratory Medicinebiologybusiness.industryKinasemedicine.diseaserespiratory tract diseases03 medical and health sciences0302 clinical medicineGefitinibEditorialEpidermal growth factor030220 oncology & carcinogenesisCancer researchbiology.proteinMedicineOsimertinibHuman medicine030212 general & internal medicineEpidermal growth factor receptorNon small cellErlotinibbusinessLung cancerneoplasmsmedicine.drugdescription
In the N Engl J Med , Soria and colleagues have recently reported the results of the phase III randomized FLAURA trial (1), comparing osimertinib with first generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) gefitinib or erlotinib in treatment-naive patients with advanced non-small cell lung cancer (NSCLC) and activating EGFR -mutations.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-04-01 |